Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience.
General Hospital Psychiatry 2026 Rebeca Cohen, João Bastos, Catarina Cunha et al. 1 citation
Ketamine, an N-methyl-d-aspartate antagonist, shows promise for treatment-resistant depression (TRD), with psychedelic doses potentially enhancing efficacy. However, its transient antidepressant effects and the need for repeated infusions raise concerns about optimal duration and long-term safety. Two clinical trials have tested the combination of ketamine with psychotherapy for depression,...